Physiologically‐Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2600
Abstract: Janus kinase (JAK) inhibitors baricitinib and tofacitinib are recommended by the US National Institutes of Health as immunomodulatory drugs for coronavirus disease 2019 (COVID‐19) treatment. In addition, baricitinib has recently received Emergency Use Authorization from… read more here.
Keywords: baricitinib; based pharmacokinetic; renal impairment; baricitinib tofacitinib ... See more keywords
Baricitinib: From Rheumatoid Arthritis to COVID‐19
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1874
Abstract: Baricitinib is a JAK1/2 inhibitor that was first approved for treating moderate to severe rheumatoid arthritis (RA) but that later showed considerable efficacy in the control of exaggerated inflammatory responses that occur in a wide… read more here.
Keywords: baricitinib; arthritis covid; rheumatoid arthritis; baricitinib rheumatoid ... See more keywords
Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
Sign Up to like & getrecommendations! Published in 2021 at "Infection"
DOI: 10.1007/s15010-021-01730-6
Abstract: The Coronavirus disease 2019 (COVID-19) pandemic is one of the most devastating global problems. Regarding the lack of disease-specific treatments, repurposing drug therapy is currently considered a promising therapeutic approach in pandemic situations. Recently, the… read more here.
Keywords: combination therapy; baricitinib; therapy; infection ... See more keywords
Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
Sign Up to like & getrecommendations! Published in 2020 at "Drug Safety"
DOI: 10.1007/s40264-020-00938-z
Abstract: The introduction of novel, small-molecule Janus kinase inhibitors namely tofacitinib, baricitinib and upadacitinib has provided an alternative treatment option for patients with rheumatoid arthritis outside of traditional drugs and expensive biologics. This review aimed to… read more here.
Keywords: baricitinib; tofacitinib baricitinib; drug; baricitinib upadacitinib ... See more keywords
Baricitinib: First Global Approval
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0723-3
Abstract: Baricitinib (Olumiant™) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus. JAKs transduce intracellular signals from… read more here.
Keywords: baricitinib; baricitinib first; treatment; global approval ... See more keywords
Efficacité et sécurité du baricitinib associé à des corticostéroïdes topiques (TCS) dans le traitement de la dermatite atopique (DA) modérée à sévère : étude de phase 3 de 16 semaines en double aveugle, randomisée et contrôlée vs placebo (BREEZE-AD7)
Sign Up to like & getrecommendations! Published in 2020 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2020.09.544
Abstract: Introduction La monotherapie par le baricitinib, un inhibiteur selectif des JAK1/2, a reduit efficacement la gravite de la DA moderee a severe lors de precedentes etudes de phase 3. L’etude de phase 3 en double aveugle, randomisee et… read more here.
Keywords: baricitinib; double aveugle; par; breeze ad7 ... See more keywords
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting.
Sign Up to like & getrecommendations! Published in 2020 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2020.106748
Abstract: BACKGROUND Baricitinib is a JAK inhibitor that blocks intracellular signalling pathways of inflammatory cytokines recommended for Rheumatoid arthritis (RA) patients not responding to initial treatment. Among RA extrareticular features, interstitial lung involvement is primarly characterized… read more here.
Keywords: baricitinib; modulatory effects; rheumatoid arthritis; real life ... See more keywords
Identification, Synthesis, and Characterization of Novel Baricitinib Impurities
Sign Up to like & getrecommendations! Published in 2023 at "ACS Omega"
DOI: 10.1021/acsomega.3c00100
Abstract: Baricitinib is a novel active pharmaceutical ingredient used in the treatment of rheumatoid arthritis, and it acts as an inhibitor of Janus kinase. During the synthesis of baricitinib, three unknown impurities were identified in several… read more here.
Keywords: characterization novel; baricitinib; synthesis characterization; synthesis ... See more keywords
Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2022 at "Current medical research and opinion"
DOI: 10.1080/03007995.2022.2135838
Abstract: BACKGROUND Since there is now no medication available that has been approved by the US Food and Drug Administration, alopecia areata (AA) is an autoimmune condition that has a detrimental impact on individuals. Recent clinical… read more here.
Keywords: meta analysis; baricitinib; analysis; effectiveness safety ... See more keywords
Efficacy of baricitinib in the treatment of rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1359256
Abstract: ABSTRACT Introduction: although the outcome for patients with rheumatoid arthritis (ra) has improved in the past decades, adequate disease control cannot be achieved in a substantial proportion of patients. new drugs with a novel mechanism… read more here.
Keywords: baricitinib; treatment; safety; efficacy ... See more keywords
Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llad129
Abstract: BACKGROUND Early prediction of therapeutic response can optimise treatment strategies in atopic dermatitis (AD). Baricitinib is approved for moderate-to-severe AD in Europe, Japan and other countries. AIM To identify early clinical improvements that reliably predict… read more here.
Keywords: clinical response; baricitinib; itch nrs; moderate severe ... See more keywords